Triple-negative breast cancer (TNBC) is characterized by lacking the expression of all three therapeutic targets, human epidermal growth factor receptor 2 (HER2), progesterone (PR), and estrogen (ER) (Ballinger et al., 2016). Here, ERBB2 is linked to triple-negative breast carcinoma.